Patients with type 1 diabetes may be protected from steatosis and hepatic insulin resistance, according to data published in the Journal of Clinical Endocrinology & Metabolism.
Further, researchers found that, unlike in type 2 diabetes, obesity may not raise insulin requirements in type 1 diabetes.
In this study, the researchers compared overweight adult patients with type 1 diabetes (n=32) with patients without diabetes (n=32). Patients were matched for age, BMI and gender.
To measure liver fat content, the researchers used proton magnetic resonance spectroscopy. They also assessed body composition using MRI and insulin sensitivity using the euglycemic hyperinsulinemic clamp technique.
Results revealed lower liver fat content in patients with type 1 diabetes vs. those without diabetes (P<.001). Additionally, the endogenous rate of glucose production during euglycemic hyperinsulinemia (P=.012) was significantly lower and the percent suppression of endogenous glucose production by insulin was significantly higher (P=.009) in patients with type 1 diabetes vs. those without diabetes.
Data also indicated that patients with type 1 diabetes had significantly lower serum non-esterified fatty acid (NEFA) concentrations during euglycemic hyperinsulinemia and significantly higher percent suppression of NEFA (P<.001) than those without diabetes.
The researchers reported that insulin doses were similar across BMI categories, according to the study.
They concluded that their results suggest that patients with type 1 diabetes may be shielded from steatosis and its adverse metabolic consequences.